---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-092665"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2023-08-16T23:59:59+00:00"
generated_at: "2026-06-11T09:02:34.248739+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gilead reports EVOKE-02 Phase 2 data: SG+Pembro 56% ORR in 1L mNSCLC

## Summary
- ORR 69% in PD-L1 TPS≥50% (Cohort A), 44% in <50% (Cohort B); overall ORR 56%.
- Median DOR not reached; 6-month DOR rate 88% in both cohorts.
- Any-grade TEAEs 100%, Grade≥3 70%; 1 treatment-related death (sepsis).
- Data inadvertently posted early by IASLC; Gilead discloses via 8-K.
- Phase 3 EVOKE-03 comparing SG+Pembro vs Pembro monotherapy is ongoing.

## SEC filing metadata
- accession: 0001104659-23-092665
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2023-08-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000110465923092665/0001104659-23-092665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000110465923092665/tm2323971d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-092665
- JSON: https://secwatch.observer/filing/0001104659-23-092665.json
- Plain text: https://secwatch.observer/filing/0001104659-23-092665.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.